UCL
uCloudlink Group Inc.
Telecommunications Services
Market Cap$43M
5Y Perf.-93.1%
Compare Stocks
3 / 10Try these comparisons:
Stock Comparison
UCL vs GSAT vs TNXP
Revenue, margins, valuation, and 5-year total return — side by side.
GSAT
Globalstar, Inc.
Telecommunications Services
Market Cap$10.33B
5Y Perf.+1562.9%
TNXP
Tonix Pharmaceuticals Holding Corp.
Biotechnology
Market Cap$31M
5Y Perf.-100.0%
UCL vs GSAT vs TNXP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | UCL | GSAT | TNXP |
|---|---|---|---|
| Industry | Telecommunications Services | Telecommunications Services | Biotechnology |
| Market Cap | $43M | $10.33B | $31M |
| Revenue (TTM) | $85M | $262M | $10M |
| Net Income (TTM) | $8M | $-50M | $-99M |
| Gross Margin | 49.8% | 57.2% | 34.3% |
| Operating Margin | -1.5% | 1.4% | -9.7% |
| Forward P/E | 104.6x | — | — |
| Total Debt | $10M | $542M | $5M |
| Cash & Equiv. | $30M | $391M | $99M |
UCL vs GSAT vs TNXP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
UCL
GSAT
TNXP
| Stock | Jun 20 | May 26 | Return |
|---|---|---|---|
| uCloudlink Group In… (UCL) | 100 | 6.9 | -93.1% |
| Globalstar, Inc. (GSAT) | 100 | 1662.9 | +1562.9% |
| Tonix Pharmaceutica… (TNXP) | 100 | 0.0 | -100.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: UCL vs GSAT vs TNXP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: UCL leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Globalstar, Inc. is the stronger pick specifically for dividend income and shareholder returns and recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
UCL
uCloudlink Group Inc.
The Defensive Pick
UCL carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 0.61, Low D/E 45.8%, current ratio 1.32x
- Beta 0.61, current ratio 1.32x
- Better valuation composite
Best for: sleep-well-at-night and defensive
GSAT
Globalstar, Inc.
The Income Pick
GSAT is the clearest fit if your priority is income & stability and long-term compounding.
- Dividend streak 2 yrs, beta 2.08, yield 0.1%
- 201.8% 10Y total return vs UCL's -93.4%
- 0.1% yield; 2-year raise streak; the other 2 pay no meaningful dividend
Best for: income & stability and long-term compounding
TNXP
Tonix Pharmaceuticals Holding Corp.
The Growth Play
TNXP is the clearest fit if your priority is growth exposure.
- Rev growth 29.9%, EPS growth 97.2%
- 29.9% revenue growth vs UCL's 7.1%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TNXP | 29.9% revenue growth vs UCL's 7.1% |
| Value | UCL | Better valuation composite |
| Quality / Margins | UCL | 9.2% margin vs TNXP's -9.6% |
| Stability / Safety | UCL | Beta 0.61 vs TNXP's 3.21 |
| Dividends | GSAT | 0.1% yield; 2-year raise streak; the other 2 pay no meaningful dividend |
| Momentum (1Y) | GSAT | +305.2% vs TNXP's -28.8% |
| Efficiency (ROA) | UCL | 11.9% ROA vs TNXP's -39.3%, ROIC 363.4% vs -150.3% |
UCL vs GSAT vs TNXP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2024
Segment breakdown not available.
UCL vs GSAT vs TNXP — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLGSATLAGGINGTNXP
TNXPTonix Pharmaceuticals…
0leads
UCLuCloudlink Group Inc.
2leads
GSATGlobalstar, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs UCLvs TNXPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
GSAT3/6
Valuation MetricsMultiples, price ratios, and targets
UCL3/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
UCL6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
GSAT6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
GSAT1/1
Income & Cash Flow (Last 12 Months)
GSAT leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
GSAT is the larger business by revenue, generating $262M annually — 25.5x TNXP's $10M. UCL is the more profitable business, keeping 9.2% of every revenue dollar as net income compared to TNXP's -9.6%. On growth, TNXP holds the edge at +16.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | UCLuCloudlink Group … | GSATGlobalstar, Inc. | TNXPTonix Pharmaceuti… |
|---|---|---|---|
| RevenueTrailing 12 months | $85M | $262M | $10M |
| EBITDAEarnings before interest/tax | $236,000 | $93M | -$98M |
| Net IncomeAfter-tax profit | $8M | -$50M | -$99M |
| Free Cash FlowCash after capex | -$5M | $151M | -$78M |
| Gross MarginGross profit ÷ Revenue | +49.8% | +57.2% | +34.3% |
| Operating MarginEBIT ÷ Revenue | -1.5% | +1.4% | -9.7% |
| Net MarginNet income ÷ Revenue | +9.2% | -19.0% | -9.6% |
| FCF MarginFCF ÷ Revenue | -6.4% | +57.6% | -7.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -16.0% | +2.1% | +16.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +21.2% | -121.9% | -14.6% |
GSAT leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
UCL leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, UCL's 3.4x EV/EBITDA is more attractive than GSAT's 119.1x.
| Metric | UCLuCloudlink Group … | GSATGlobalstar, Inc. | TNXPTonix Pharmaceuti… |
|---|---|---|---|
| Market CapShares × price | $43M | $10.3B | $31M |
| Enterprise ValueMkt cap + debt − cash | $23M | $10.5B | -$63M |
| Trailing P/EPrice ÷ TTM EPS | 0.95x | -138.10x | -0.08x |
| Forward P/EPrice ÷ next-FY EPS est. | 104.59x | — | — |
| PEG RatioP/E ÷ EPS growth rate | 0.02x | — | — |
| EV / EBITDAEnterprise value multiple | 3.39x | 119.09x | — |
| Price / SalesMarket cap ÷ Revenue | 0.47x | 41.28x | 3.05x |
| Price / BookPrice ÷ Book value/share | 1.98x | 28.58x | 0.22x |
| Price / FCFMarket cap ÷ FCF | 8.27x | 57.85x | — |
UCL leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
UCL leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
UCL delivers a 32.4% return on equity — every $100 of shareholder capital generates $32 in annual profit, vs $-43 for TNXP. TNXP carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to GSAT's 1.51x. On the Piotroski fundamental quality scale (0–9), UCL scores 5/9 vs TNXP's 4/9, reflecting solid financial health.
| Metric | UCLuCloudlink Group … | GSATGlobalstar, Inc. | TNXPTonix Pharmaceuti… |
|---|---|---|---|
| ROE (TTM)Return on equity | +32.4% | -13.7% | -42.9% |
| ROA (TTM)Return on assets | +11.9% | -2.3% | -39.3% |
| ROICReturn on invested capital | +3.6% | -0.1% | -150.3% |
| ROCEReturn on capital employed | +21.8% | -0.1% | -97.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.46x | 1.51x | 0.04x |
| Net DebtTotal debt minus cash | -$20M | $151M | -$93M |
| Cash & Equiv.Liquid assets | $30M | $391M | $99M |
| Total DebtShort + long-term debt | $10M | $542M | $5M |
| Interest CoverageEBIT ÷ Interest expense | 22.37x | -0.07x | — |
UCL leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
GSAT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GSAT five years ago would be worth $49,382 today (with dividends reinvested), compared to $0 for TNXP. Over the past 12 months, GSAT leads with a +305.2% total return vs TNXP's -28.8%. The 3-year compound annual growth rate (CAGR) favors GSAT at 80.1% vs TNXP's -89.0% — a key indicator of consistent wealth creation.
| Metric | UCLuCloudlink Group … | GSATGlobalstar, Inc. | TNXPTonix Pharmaceuti… |
|---|---|---|---|
| YTD ReturnYear-to-date | -31.3% | +27.3% | -17.7% |
| 1-Year ReturnPast 12 months | -2.6% | +305.2% | -28.8% |
| 3-Year ReturnCumulative with dividends | -72.9% | +484.1% | -99.9% |
| 5-Year ReturnCumulative with dividends | -89.3% | +393.8% | -100.0% |
| 10-Year ReturnCumulative with dividends | -93.4% | +201.8% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -35.3% | +80.1% | -89.0% |
GSAT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — UCL and GSAT each lead in 1 of 2 comparable metrics.
Risk & Volatility
UCL is the less volatile stock with a 0.61 beta — it tends to amplify market swings less than TNXP's 3.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GSAT currently trades 98.3% from its 52-week high vs TNXP's 19.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | UCLuCloudlink Group … | GSATGlobalstar, Inc. | TNXPTonix Pharmaceuti… |
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.61x | 2.08x | 3.21x |
| 52-Week HighHighest price in past year | $4.19 | $82.85 | $69.97 |
| 52-Week LowLowest price in past year | $1.10 | $17.24 | $11.60 |
| % of 52W HighCurrent price vs 52-week peak | +27.2% | +98.3% | +19.5% |
| RSI (14)Momentum oscillator 0–100 | 29.1 | 66.4 | 58.9 |
| Avg Volume (50D)Average daily shares traded | 7K | 1.5M | 413K |
Evenly matched — UCL and GSAT each lead in 1 of 2 comparable metrics.
Analyst Outlook
GSAT leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: GSAT as "Hold", TNXP as "Buy". GSAT is the only dividend payer here at 0.10% yield — a key consideration for income-focused portfolios.
| Metric | UCLuCloudlink Group … | GSATGlobalstar, Inc. | TNXPTonix Pharmaceuti… |
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Buy |
| Price TargetConsensus 12-month target | — | $66.00 | — |
| # AnalystsCovering analysts | — | 5 | 7 |
| Dividend YieldAnnual dividend ÷ price | — | +0.1% | — |
| Dividend StreakConsecutive years of raises | — | 2 | 0 |
| Dividend / ShareAnnual DPS | — | $0.08 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% |
GSAT leads this category, winning 1 of 1 comparable metric.
Key Takeaway
GSAT leads in 3 of 6 categories (Income & Cash Flow, Total Returns). UCL leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
Best OverallGlobalstar, Inc. (GSAT)Leads 3 of 6 categories
Loading custom metrics...
UCL vs GSAT vs TNXP: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is UCL or GSAT or TNXP a better buy right now?
For growth investors, Tonix Pharmaceuticals Holding Corp.
(TNXP) is the stronger pick with 29. 9% revenue growth year-over-year, versus 7. 1% for uCloudlink Group Inc. (UCL). uCloudlink Group Inc. (UCL) offers the better valuation at 0. 9x trailing P/E (104. 6x forward), making it the more compelling value choice. Analysts rate Tonix Pharmaceuticals Holding Corp. (TNXP) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — UCL or GSAT or TNXP?
Over the past 5 years, Globalstar, Inc.
(GSAT) delivered a total return of +393. 8%, compared to -100. 0% for Tonix Pharmaceuticals Holding Corp. (TNXP). Over 10 years, the gap is even starker: GSAT returned +201. 8% versus TNXP's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — UCL or GSAT or TNXP?
By beta (market sensitivity over 5 years), uCloudlink Group Inc.
(UCL) is the lower-risk stock at 0. 61β versus Tonix Pharmaceuticals Holding Corp. 's 3. 21β — meaning TNXP is approximately 423% more volatile than UCL relative to the S&P 500. On balance sheet safety, Tonix Pharmaceuticals Holding Corp. (TNXP) carries a lower debt/equity ratio of 4% versus 151% for Globalstar, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — UCL or GSAT or TNXP?
By revenue growth (latest reported year), Tonix Pharmaceuticals Holding Corp.
(TNXP) is pulling ahead at 29. 9% versus 7. 1% for uCloudlink Group Inc. (UCL). On earnings-per-share growth, the picture is similar: uCloudlink Group Inc. grew EPS 1479% year-over-year, compared to -195. 0% for Globalstar, Inc.. Over a 3-year CAGR, GSAT leads at 26. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — UCL or GSAT or TNXP?
uCloudlink Group Inc.
(UCL) is the more profitable company, earning 5. 0% net margin versus -1288. 3% for Tonix Pharmaceuticals Holding Corp. — meaning it keeps 5. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UCL leads at 4. 8% versus -1354. 3% for TNXP. At the gross margin level — before operating expenses — GSAT leads at 66. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — UCL or GSAT or TNXP?
In this comparison, GSAT (0.
1% yield) pays a dividend. UCL, TNXP do not pay a meaningful dividend and should not be held primarily for income.
07Is UCL or GSAT or TNXP better for a retirement portfolio?
For long-horizon retirement investors, uCloudlink Group Inc.
(UCL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 61)). Tonix Pharmaceuticals Holding Corp. (TNXP) carries a higher beta of 3. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (UCL: -93. 4%, TNXP: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between UCL and GSAT and TNXP?
These companies operate in different sectors (UCL (Communication Services) and GSAT (Communication Services) and TNXP (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: UCL is a small-cap deep-value stock; GSAT is a mid-cap quality compounder stock; TNXP is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(UCL: -16.0% · GSAT: 2.1%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.